Spotlight on Oncology

Credits: 1 CME / CNE / CPE
Applying Recent Advances in Treating Relapsed or Refractory Multiple Myeloma Into Real World Practice
Rush University Medical Center

Applying Recent Advances in Treating Relapsed or Refractory Multiple Myeloma Into Real World Practice

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 22, 2021
Expires: October 21, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest developments in the treatment of relapsed/refractory multiple myeloma and the impact on clinical practice
  2. Discuss approaches to managing multiple myeloma patients at the time of first relapse, as well as management considerations for heavily pretreated and multi-refractory patients
  3. Describe promising emerging therapies for the treatment of multiple myeloma and their potential roles in the context of existing relapsed/refractory treatment paradigms
  4. Implement the latest best-practice strategies for relapsed/refractory multiple myeloma, taking into consideration patient-, disease-, and treatment-related factors to individualize care throughout the disease continuum

Activity Description

The treatment paradigm for multiple myeloma (MM) is complex and evolving in light of both the continual introduction of novel agents and regimens, and enhanced patient profiling information. With many more agents in clinical development, this complexity will continue to grow. Studies in this area are increasing rapidly and keeping up with the information is an arduous task. To ensure optimal utilization of current and investigational therapeutic modalities, this activity will help keep clinicians abreast of the most effective means to utilize and integrate these treatment modalities into everyday clinical practice. This easy-to-follow and practical presentation summarizing the updates in the field will greatly benefit those providers who care for patients with relapsed/refractory MM.

Statement of Educational Need

The rapid advancements in therapeutic options for the management of patients with multiple myeloma have the potential to enhance clinical outcomes and patient quality of life. The challenge of bridging the knowledge gap between the latest evidence-based information and current practice is an enormous hurdle that the majority of community healthcare providers struggle with and often fall short in accomplishing. Many learning barriers are related to limited access to research data, time-restrictions among busy clinicians, and difficulty translating research data for application into practice. To provide optimal care, these healthcare professionals need expert guidance to improve their understanding of how current and novel treatment modalities can be utilized in the most effective way and their ability to plan strategies to incorporate them into everyday clinical practice.

Faculty

C. Ola Landgren, MD, PhD
Professor, Leader of Experimental Therapeutics Program & Leader of Myeloma Service
Sylvester Comprehensive Cancer Center
University of Miami Health System
Miami, FL

Research Grant: Amgen, Celgene, Janssen, Takeda
Advisory Board: GSK, Amgen, Sanofi, BMS, AstraZeneca
Independent Data Monitoring Committee (IDMC) member for clinical trials: Janssen, Takeda, and Merck

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this online activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this online activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this online activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc., Karyopharm Therapeutics, Oncopeptides, and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 22, 2021
Expires: October 21, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  1. Evaluate the latest developments in the treatment of relapsed/refractory multiple myeloma and the impact on clinical practice
  2. Discuss approaches to managing multiple myeloma patients at the time of first relapse, as well as management considerations for heavily pretreated and multi-refractory patients
  3. Describe promising emerging therapies for the treatment of multiple myeloma and their potential roles in the context of existing relapsed/refractory treatment paradigms
  4. Implement the latest best-practice strategies for relapsed/refractory multiple myeloma, taking into consideration patient-, disease-, and treatment-related factors to individualize care throughout the disease continuum

Activity Description

The treatment paradigm for multiple myeloma (MM) is complex and evolving in light of both the continual introduction of novel agents and regimens, and enhanced patient profiling information. With many more agents in clinical development, this complexity will continue to grow. Studies in this area are increasing rapidly and keeping up with the information is an arduous task. To ensure optimal utilization of current and investigational therapeutic modalities, this activity will help keep clinicians abreast of the most effective means to utilize and integrate these treatment modalities into everyday clinical practice. This easy-to-follow and practical presentation summarizing the updates in the field will greatly benefit those providers who care for patients with relapsed/refractory MM.

Statement of Educational Need

The rapid advancements in therapeutic options for the management of patients with multiple myeloma have the potential to enhance clinical outcomes and patient quality of life. The challenge of bridging the knowledge gap between the latest evidence-based information and current practice is an enormous hurdle that the majority of community healthcare providers struggle with and often fall short in accomplishing. Many learning barriers are related to limited access to research data, time-restrictions among busy clinicians, and difficulty translating research data for application into practice. To provide optimal care, these healthcare professionals need expert guidance to improve their understanding of how current and novel treatment modalities can be utilized in the most effective way and their ability to plan strategies to incorporate them into everyday clinical practice.

Faculty

C. Ola Landgren, MD, PhD
Professor, Leader of Experimental Therapeutics Program & Leader of Myeloma Service
Sylvester Comprehensive Cancer Center
University of Miami Health System
Miami, FL

Research Grant: Amgen, Celgene, Janssen, Takeda
Advisory Board: GSK, Amgen, Sanofi, BMS, AstraZeneca
Independent Data Monitoring Committee (IDMC) member for clinical trials: Janssen, Takeda, and Merck

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this online activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this online activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this online activity for a maximum of one (1) continuing education unit(s) in Pharmacy.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc., Karyopharm Therapeutics, Oncopeptides, and Sanofi Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in healthcare and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Oncology Presentations

1.00 CME / CNE / CPE
Rush University Medical Center
Evolving Standards of Care in Advanced Prostate Cancer: Incorporating the Latest Therapeutic Strategies

Evolving Standards of Care in Advanced Prostate Cancer: Incorporating the Latest Therapeutic Strategies

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 10, 2021
Expires: May 9, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Assess the latest advances in mHSPC and CRPC treatment paradigms including the efficacy, safety, selection, and application of new and emerging approaches in order to best integrate them into care
  2. Differentiate among available and emerging treatment approaches for mHSPC and CRPC
  3. Formulate best-practice treatment strategies for mHSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementof advanced prostate cancer.This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The concurrent development of many treatments for advanced prostate cancer within a short period of time has made prospective data on their sequential use and efficacy complicated, which have challenged clinician confidence, knowledge, and competency. The increasingly complex prostate cancer treatment milieu is marked by limited sequencing or combination trials, an increasingly complex understanding of disease pathophysiology and genomic profiling, and emerging therapeutics with novel mechanisms of action.

Understanding the available treatments, both current and emerging, and how these agents interface with disease pathophysiology to drive a more personalized medicine approach remain significant challenges for urologists and oncologists who treat patients with advanced prostate cancer.

Faculty

Elizabeth Henry, MD
Associate Professor
Fellowship Program Director, Hematology/Oncology
Quality Medical Director, Hematology/Oncology
Loyola University Medical Center
Maywood, IL

Disclosure: Dr. Henry has no conflict of interests to disclose.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This educational activity is supported by medical education grants from Astellas and Pfizer, Inc., and Sanofi-Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: May 10, 2021
Expires: May 9, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with advanced prostate cancer.

Learning Objectives

After completing this program, participants should be able to:

  1. Assess the latest advances in mHSPC and CRPC treatment paradigms including the efficacy, safety, selection, and application of new and emerging approaches in order to best integrate them into care
  2. Differentiate among available and emerging treatment approaches for mHSPC and CRPC
  3. Formulate best-practice treatment strategies for mHSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the managementof advanced prostate cancer.This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

The concurrent development of many treatments for advanced prostate cancer within a short period of time has made prospective data on their sequential use and efficacy complicated, which have challenged clinician confidence, knowledge, and competency. The increasingly complex prostate cancer treatment milieu is marked by limited sequencing or combination trials, an increasingly complex understanding of disease pathophysiology and genomic profiling, and emerging therapeutics with novel mechanisms of action.

Understanding the available treatments, both current and emerging, and how these agents interface with disease pathophysiology to drive a more personalized medicine approach remain significant challenges for urologists and oncologists who treat patients with advanced prostate cancer.

Faculty

Elizabeth Henry, MD
Associate Professor
Fellowship Program Director, Hematology/Oncology
Quality Medical Director, Hematology/Oncology
Loyola University Medical Center
Maywood, IL

Disclosure: Dr. Henry has no conflict of interests to disclose.

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This educational activity is supported by medical education grants from Astellas and Pfizer, Inc., and Sanofi-Genzyme.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.00 CME / CNE / CPE
Rush University Medical Center
Expert Perspectives on Treating High-Risk and Relapsed/Refractory Acute Myeloid Leukemia

Expert Perspectives on Treating High-Risk and Relapsed/Refractory Acute Myeloid Leukemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: April 30, 2021
Expires: April 29, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with acute myeloid leukemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize recommendations for molecular and cytogenic testing of patients with AML and how these results can be used to inform treatment decisions.
  2. Formulate informed treatment plans for patients with high-risk or relapsed/refractory AML, taking into consideration the latest clinical evidence regarding the safety and efficacy of recently approved therapies.
  3. Assess late-phase clinical trial data on investigational therapies and novel combination approaches within the context of existing AML treatment paradigms.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of acute myeloid leukemia.This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

High-risk and relapsed/refractory AML represent significant clinical challenges. Within the past several years, eight novel agents have been approved for the treatment of AML, providing hope for improved outcomes in the coming years. With the wide variety of agents under development for the treatment of high-risk and relapsed/refractory AML, the use of recently approved and investigational agents is anticipated to continue to expand over the next few years. To continue to provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the utility of agents that could significantly impact clinical practice.

Faculty

Eytan M. Stein, MD
Director, Program for Drug Development in Leukemia
Assistant Professor
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Stein has consulted for:
Syndax, Syros, Novartis, Astellas, Daiichi, Gilead, Abbvie, Genentech, Janssen, BMS, Celgene, Agios, Blueprint, Neoleukin, PinotBio

Dr. Stein has research grants from:
Bayer, Syndax, Novartis, Biotheryx, Gilead, Agios

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from AbbVie Inc., Agios Pharmaceuticals, Inc., and Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: April 30, 2021
Expires: April 29, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists, and other healthcare professionals involved in the treatment of patients with acute myeloid leukemia.

Learning Objectives

After completing this program, participants should be able to:

  1. Summarize recommendations for molecular and cytogenic testing of patients with AML and how these results can be used to inform treatment decisions.
  2. Formulate informed treatment plans for patients with high-risk or relapsed/refractory AML, taking into consideration the latest clinical evidence regarding the safety and efficacy of recently approved therapies.
  3. Assess late-phase clinical trial data on investigational therapies and novel combination approaches within the context of existing AML treatment paradigms.

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of acute myeloid leukemia.This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

High-risk and relapsed/refractory AML represent significant clinical challenges. Within the past several years, eight novel agents have been approved for the treatment of AML, providing hope for improved outcomes in the coming years. With the wide variety of agents under development for the treatment of high-risk and relapsed/refractory AML, the use of recently approved and investigational agents is anticipated to continue to expand over the next few years. To continue to provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the utility of agents that could significantly impact clinical practice.

Faculty

Eytan M. Stein, MD
Director, Program for Drug Development in Leukemia
Assistant Professor
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Stein has consulted for:
Syndax, Syros, Novartis, Astellas, Daiichi, Gilead, Abbvie, Genentech, Janssen, BMS, Celgene, Agios, Blueprint, Neoleukin, PinotBio

Dr. Stein has research grants from:
Bayer, Syndax, Novartis, Biotheryx, Gilead, Agios

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

Supported by educational grants from AbbVie Inc., Agios Pharmaceuticals, Inc., and Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.75 CME / MOC
Postgraduate Institute for Medicine
Basal Cell Carcinoma: To Targeted Therapy and Beyond—Advanced Basal Cell Carcinoma: Navigating an Evolving Therapeutic Landscape

Basal Cell Carcinoma: To Targeted Therapy and Beyond—Advanced Basal Cell Carcinoma: Navigating an Evolving Therapeutic Landscape

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
ABIM MOC Points
Released: April 9, 2021
Expires: April 8, 2022
45 minutes to complete

Jointly Provided By

Jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of dermatology and oncology physicians who diagnose and manage patients with advanced basal cell carcinoma (BCC).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Apply current data to the appropriate selection of Hedgehog inhibitors in advanced basal cell carcinoma (BCC)
  • Evaluate the role and place of immunotherapy in managing patients with advanced BCC

Activity Description

Therapeutic options for advanced basal cell carcinoma (BCC) have been transformed by the introduction of Hedgehog pathway inhibitors (HPIs) and the emergence of immunotherapy. Led by a multidisciplinary expert panel, this activity uniquely features an experienced patient sharing key insights from their treatment journey. The discussion focuses on the role and place of HPIs and PD-1 inhibitors in advanced BCC and provides professional guidance on managing class-specific toxicities, including immune-mediated adverse events.

Statement of Educational Need

Healthcare providers require expert insights on current safety and efficacy data to guide appropriate selection and use of Hedgehog pathway inhibitors in advanced basal cell carcinoma (BCC). The advent of immunotherapy necessitates education with respect to its role and place in the treatment armamentarium, as well as professional guidance on strategies to proactively identify and manage immune-related adverse events.

Chair

Omid Hamid, MD
Chief, Translational Research and Immunotherapy
Director, Melanoma Center and Phase I Immuno-Oncology Program
The Angeles Clinic and Research Institute
Los Angeles, CA

Disclosure:
Speakers Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron
Consulting Fees: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Genentech, GSK, Immunocore, Idera, Incyste, Jannsen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Tempus, Zelluna

Faculty

Mario Lacouture, MD
Director, Oncodermatology Program
Professor of Dermatology
Memorial Sloan Kettering Cancer Center
New York City, NY

Disclosure:
Consultant Fees: Apricity, AstraZeneca, Azitra, Bicara, Deciphera, DFB, EMD Serono, F. Hoffmann-La Roche AG, Genentech, Innovaderm, Janssen, Johnson & Johnson, Kintara, Loxo, Lutris, NCODA, Novartis, Novocure, Oncoderm, OnQuality, QED, RBC/La Roche Posay, Roche, Seattle Genetics, Trifecta, Varsona
Research Funding: AstraZeneca, Johnson & Johnson, Lutris, Novartis, Novocure, OQL, Paxman, US Biotest, and is funded in part through NIH/NIAMS grant U01 AR077511 and the NIH/NCI Cancer Center Support Grant P30 CA008748


Michelle Offner, RN, MSN, ACNP-BC
Nurse Practitioner, Medical Oncology (Cutaneous Malignancies)
The Angeles Clinic and Research Institute
Los Angeles, CA

Disclosure:
Consulting Fees: Boston BioMed, Sanofi/Regeneron

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The RMEI Medical Education planners and others have nothing to disclose. The patient in this activity has nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com. For accreditation questions, please contact PIM at inquiries@pimed.com.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
ABIM MOC Points
Released: April 9, 2021
Expires: April 8, 2022
45 minutes to complete

Jointly Provided By

Jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the educational needs of dermatology and oncology physicians who diagnose and manage patients with advanced basal cell carcinoma (BCC).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Apply current data to the appropriate selection of Hedgehog inhibitors in advanced basal cell carcinoma (BCC)
  • Evaluate the role and place of immunotherapy in managing patients with advanced BCC

Activity Description

Therapeutic options for advanced basal cell carcinoma (BCC) have been transformed by the introduction of Hedgehog pathway inhibitors (HPIs) and the emergence of immunotherapy. Led by a multidisciplinary expert panel, this activity uniquely features an experienced patient sharing key insights from their treatment journey. The discussion focuses on the role and place of HPIs and PD-1 inhibitors in advanced BCC and provides professional guidance on managing class-specific toxicities, including immune-mediated adverse events.

Statement of Educational Need

Healthcare providers require expert insights on current safety and efficacy data to guide appropriate selection and use of Hedgehog pathway inhibitors in advanced basal cell carcinoma (BCC). The advent of immunotherapy necessitates education with respect to its role and place in the treatment armamentarium, as well as professional guidance on strategies to proactively identify and manage immune-related adverse events.

Chair

Omid Hamid, MD
Chief, Translational Research and Immunotherapy
Director, Melanoma Center and Phase I Immuno-Oncology Program
The Angeles Clinic and Research Institute
Los Angeles, CA

Disclosure:
Speakers Bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron
Consulting Fees: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Genentech, GSK, Immunocore, Idera, Incyste, Jannsen, Merck, Nextcure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Tempus, Zelluna

Faculty

Mario Lacouture, MD
Director, Oncodermatology Program
Professor of Dermatology
Memorial Sloan Kettering Cancer Center
New York City, NY

Disclosure:
Consultant Fees: Apricity, AstraZeneca, Azitra, Bicara, Deciphera, DFB, EMD Serono, F. Hoffmann-La Roche AG, Genentech, Innovaderm, Janssen, Johnson & Johnson, Kintara, Loxo, Lutris, NCODA, Novartis, Novocure, Oncoderm, OnQuality, QED, RBC/La Roche Posay, Roche, Seattle Genetics, Trifecta, Varsona
Research Funding: AstraZeneca, Johnson & Johnson, Lutris, Novartis, Novocure, OQL, Paxman, US Biotest, and is funded in part through NIH/NIAMS grant U01 AR077511 and the NIH/NCI Cancer Center Support Grant P30 CA008748


Michelle Offner, RN, MSN, ACNP-BC
Nurse Practitioner, Medical Oncology (Cutaneous Malignancies)
The Angeles Clinic and Research Institute
Los Angeles, CA

Disclosure:
Consulting Fees: Boston BioMed, Sanofi/Regeneron

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The RMEI Medical Education planners and others have nothing to disclose. The patient in this activity has nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

Please contact Nicole Neely at nneely@rmei.com. For accreditation questions, please contact PIM at inquiries@pimed.com.

0.75 CME
Integrity Continuing Education, Inc.
Unlocking Epigenetic Secrets from the Womb: Therapeutic Options for Advanced and Recurrent Endometrial Cancer

Unlocking Epigenetic Secrets from the Womb: Therapeutic Options for Advanced and Recurrent Endometrial Cancer

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: April 8, 2021
Expires: April 8, 2022
45 minutes to complete

Accredited By

Provided by Integrity Continuing Education, Inc.

Statement of Commercial Support

Supported by independent educational grants from Eisai, GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Target Audience

This program is intended for medical oncologists, gynecologic oncologists, primary care physicians, advanced practice providers, emergency department physicians, and pharmacists involved in the management and treatment of patients with endometrial cancer (EC).

Learning Objectives

  • Identifyboth preventable and inescapable risk factors that drive mortality rates in advanced and recurrent EC
  • Select appropriate and individualized treatment approaches for each EC patient based genomic subtypes and molecular markers
  • Developa strategy for identifying and addressing adverse events caused by immunotherapy and/or combination treatments
  • Incorporatea patient-centric treatment approach that considers each woman’s well-being and quality of life

Activity Description

Previously hidden epigenetic alterations of a more malevolent and disordered nature can result in EC, the most common gynecologic malignancy in the United States. Recent unraveling of the molecular profile of EC and its tumor microenvironment has revealed the immunologic nature of this disease, showing that up to 91% of patients with advanced or recurrent EC have at least one genetic mutation that can serve as an actionable therapeutic target. Indeed, unlocking the epigenetic secrets of advanced and recurrent EC has shown this disease to be highly immunogenic, making this gynecologic cancer an ideal candidate for immunotherapy. Consequently, immunotherapy with immune checkpoint inhibitors (ICIs) are being researched as both monotherapy and in synergistic combinations with cytotoxic, hormonal, and targeted treatments for greater efficacy and improved survival outcomes.

In this case-based activity, clinicians will have the opportunity to navigate a simulated patient case, making clinical decisions about diagnosis, testing, and treatment when prompted. Feedback regarding decisions made will be provided as they move through the case.

Faculty

Don S. Dizon, MD, FACP, FASCO
Professor of Medicine
Brown University
Director, Women’s Cancers & Hematology-Oncology Outpatient Clinics
Lifespan Cancer Institute
Director, Medical Oncology & Oncology Sexual Health Program
Rhode Island Hospital
Providence, Rhode Island


Shannon N. Westin, MD, MPH (Faculty Chair)
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology & Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Don S. Dizon, MD, FACP, FASCO
Consulting Fees: AstraZeneca, Clovis, Regeneron
Contracted Research: Bristol-Myers Squibb, Kazia, Pfizer, Tesaro (Institutional funds)

Shannon N. Westin, MD, MPH, has no real or apparent conflicts of interest to disclose.

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 8, 2021 through April 8, 2022 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit
Released: April 8, 2021
Expires: April 8, 2022
45 minutes to complete

Accredited By

Provided by Integrity Continuing Education, Inc.

Statement of Commercial Support

Supported by independent educational grants from Eisai, GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Target Audience

This program is intended for medical oncologists, gynecologic oncologists, primary care physicians, advanced practice providers, emergency department physicians, and pharmacists involved in the management and treatment of patients with endometrial cancer (EC).

Learning Objectives

  • Identifyboth preventable and inescapable risk factors that drive mortality rates in advanced and recurrent EC
  • Select appropriate and individualized treatment approaches for each EC patient based genomic subtypes and molecular markers
  • Developa strategy for identifying and addressing adverse events caused by immunotherapy and/or combination treatments
  • Incorporatea patient-centric treatment approach that considers each woman’s well-being and quality of life

Activity Description

Previously hidden epigenetic alterations of a more malevolent and disordered nature can result in EC, the most common gynecologic malignancy in the United States. Recent unraveling of the molecular profile of EC and its tumor microenvironment has revealed the immunologic nature of this disease, showing that up to 91% of patients with advanced or recurrent EC have at least one genetic mutation that can serve as an actionable therapeutic target. Indeed, unlocking the epigenetic secrets of advanced and recurrent EC has shown this disease to be highly immunogenic, making this gynecologic cancer an ideal candidate for immunotherapy. Consequently, immunotherapy with immune checkpoint inhibitors (ICIs) are being researched as both monotherapy and in synergistic combinations with cytotoxic, hormonal, and targeted treatments for greater efficacy and improved survival outcomes.

In this case-based activity, clinicians will have the opportunity to navigate a simulated patient case, making clinical decisions about diagnosis, testing, and treatment when prompted. Feedback regarding decisions made will be provided as they move through the case.

Faculty

Don S. Dizon, MD, FACP, FASCO
Professor of Medicine
Brown University
Director, Women’s Cancers & Hematology-Oncology Outpatient Clinics
Lifespan Cancer Institute
Director, Medical Oncology & Oncology Sexual Health Program
Rhode Island Hospital
Providence, Rhode Island


Shannon N. Westin, MD, MPH (Faculty Chair)
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology & Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Don S. Dizon, MD, FACP, FASCO
Consulting Fees: AstraZeneca, Clovis, Regeneron
Contracted Research: Bristol-Myers Squibb, Kazia, Pfizer, Tesaro (Institutional funds)

Shannon N. Westin, MD, MPH, has no real or apparent conflicts of interest to disclose.

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of April 8, 2021 through April 8, 2022 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

0.50 CME
AKH Inc., Advancing Knowledge in Healthcare
HER2 Testing in Gastric Cancer: A Survival Guide to Interpretation and Application

HER2 Testing in Gastric Cancer: A Survival Guide to Interpretation and Application

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: April 2, 2021
Expires: April 1, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncology clinicians and other healthcare professionals who diagnose and/or manage patients with gastric cancer.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Assess current HER2 testing recommendations and strategies for gastric cancer
  • Apply optimal testing and interpretation strategies to identify patients with gastric cancer that could benefit from HER2-directed therapy
  • Identify current and emerging HER2-directed therapies for gastric cancer

Activity Description

In this activity, a panel of experts discuss current methods for determining the HER2 status of gastric adenocarcinomas and/or gastroesophageal junction cancers and the implications of these findings on treatment selection in the first-line setting and beyond.

Statement of Educational Need

HER2 testing volume has been found to be significantly lower in community-based centers than academic settings. Given the rapidly changing landscape of HER2 targeted therapy for the treatment of gastric cancer, it is essential to narrow the knowledge and testing gaps among clinicians who manage individuals with gastric adenocarcinomas or gastroesophageal cancers.

Activity Chair

Richard Kim, MD
Service Chief and Senior Staff, Gastrointestinal Oncology
H. Lee Moffitt Cancer Center
Professor, University of South Florida
Tampa, FL

Faculty

Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
University of Chicago Medical Center
Chicago, IL


Laura H. Tang, MD, PhD
Attending Pathologist
Memorial Sloan Kettering Cancer Center
Professor, Pathology
Will Cornell Medical College
New York, NY

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Richard Kim, MD, has affiliations with BMS, Lilly (Consultant); Bayer, BMS, Eisai (Contracted Research); Incyte (Speakers Bureau).

Daniel Catenacci, MD, has affiliations withAmgen, Archer & Natera, Astellas, BMS, Daiichi Sankyo, Lilly, Five Prime, Foundation Medicine, Guardant Health, Genentech/Roche, Gritstone, Merck, Pieris, QED, Taiho, Tempus, Zymeworks (Consultant); Genentech/Roche, Guardant Health, Lilly, Merck, Tempus (Speakers Bureau).

Laura H. Tang, MD, PhD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Kim Farina, PhD, Medical Writer, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 70% or higher on the post-test to receive credit for this activity.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: April 2, 2021
Expires: April 1, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncology clinicians and other healthcare professionals who diagnose and/or manage patients with gastric cancer.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Assess current HER2 testing recommendations and strategies for gastric cancer
  • Apply optimal testing and interpretation strategies to identify patients with gastric cancer that could benefit from HER2-directed therapy
  • Identify current and emerging HER2-directed therapies for gastric cancer

Activity Description

In this activity, a panel of experts discuss current methods for determining the HER2 status of gastric adenocarcinomas and/or gastroesophageal junction cancers and the implications of these findings on treatment selection in the first-line setting and beyond.

Statement of Educational Need

HER2 testing volume has been found to be significantly lower in community-based centers than academic settings. Given the rapidly changing landscape of HER2 targeted therapy for the treatment of gastric cancer, it is essential to narrow the knowledge and testing gaps among clinicians who manage individuals with gastric adenocarcinomas or gastroesophageal cancers.

Activity Chair

Richard Kim, MD
Service Chief and Senior Staff, Gastrointestinal Oncology
H. Lee Moffitt Cancer Center
Professor, University of South Florida
Tampa, FL

Faculty

Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
University of Chicago Medical Center
Chicago, IL


Laura H. Tang, MD, PhD
Attending Pathologist
Memorial Sloan Kettering Cancer Center
Professor, Pathology
Will Cornell Medical College
New York, NY

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Richard Kim, MD, has affiliations with BMS, Lilly (Consultant); Bayer, BMS, Eisai (Contracted Research); Incyte (Speakers Bureau).

Daniel Catenacci, MD, has affiliations withAmgen, Archer & Natera, Astellas, BMS, Daiichi Sankyo, Lilly, Five Prime, Foundation Medicine, Guardant Health, Genentech/Roche, Gritstone, Merck, Pieris, QED, Taiho, Tempus, Zymeworks (Consultant); Genentech/Roche, Guardant Health, Lilly, Merck, Tempus (Speakers Bureau).

Laura H. Tang, MD, PhD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Kim Farina, PhD, Medical Writer, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 70% or higher on the post-test to receive credit for this activity.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

1.00 CME / CNE / CPE
Rush University Medical Center
Clinical Strategies to Optimize Outcomes Across the Disease Spectrum in Multiple Myeloma

Clinical Strategies to Optimize Outcomes Across the Disease Spectrum in Multiple Myeloma

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: March 9, 2021
Expires: March 8, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  1. Develop individualized treatment plans for MM patients in the VHA, DoD and MHS settings based on risk and cytogenetic and genomic data
  2. Recognize the disease-, treatment-, and patient-related factors that affect risk stratification and the selection and sequencing of novel drug combination therapies across the disease spectrum for multiple myeloma
  3. Evaluate emerging clinical data and describe risk/benefit of current and evolving treatment approaches across the disease spectrum of multiple myeloma

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With a significant number of new drug approvals and label-updates since 2015, the multiple myeloma (MM) treatment landscape is rapidly evolving. New therapeutic options have resulted in improved clinical outcomes for patients with multiple myeloma and have transformed this disease into a chronic condition that can be managed over a longer course of years. As an increasing number of clinical trials are progressing, treatments for multiple myeloma will continue to improve and current treatment algorithms will continue to evolve.

The goal of this activity is to provide clinicians with insights into the decision-making strategies necessary to make best use of available therapeutic options in an individual patient and how and when treatments can be combined to improve control of the underlying disease.

Faculty

Jeffrey V. Matous, MD
Medical Director, Colorado Blood Cancer Institute
Clinical Professor of Medicine
University of Colorado Health Sciences Center
Denver, CO


Conflict of Interest Policy/Disclosure Statement

Research Grant: Pharmacyclics
Consultant: Pharmacyclics

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb and Karyopharm Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: March 9, 2021
Expires: March 8, 2022
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with multiple myeloma.

Learning Objectives

After completing this program, participants should be able to:

  1. Develop individualized treatment plans for MM patients in the VHA, DoD and MHS settings based on risk and cytogenetic and genomic data
  2. Recognize the disease-, treatment-, and patient-related factors that affect risk stratification and the selection and sequencing of novel drug combination therapies across the disease spectrum for multiple myeloma
  3. Evaluate emerging clinical data and describe risk/benefit of current and evolving treatment approaches across the disease spectrum of multiple myeloma

Activity Description

This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of multiple myeloma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

With a significant number of new drug approvals and label-updates since 2015, the multiple myeloma (MM) treatment landscape is rapidly evolving. New therapeutic options have resulted in improved clinical outcomes for patients with multiple myeloma and have transformed this disease into a chronic condition that can be managed over a longer course of years. As an increasing number of clinical trials are progressing, treatments for multiple myeloma will continue to improve and current treatment algorithms will continue to evolve.

The goal of this activity is to provide clinicians with insights into the decision-making strategies necessary to make best use of available therapeutic options in an individual patient and how and when treatments can be combined to improve control of the underlying disease.

Faculty

Jeffrey V. Matous, MD
Medical Director, Colorado Blood Cancer Institute
Clinical Professor of Medicine
University of Colorado Health Sciences Center
Denver, CO


Conflict of Interest Policy/Disclosure Statement

Research Grant: Pharmacyclics
Consultant: Pharmacyclics

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb and Karyopharm Therapeutics, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

0.75 CME
University of Nebraska Medical Center
On Topic Virtual Roundtable: Multidisciplinary Approaches and Thoughts on the Care of HER2+ Breast Cancer

On Topic Virtual Roundtable: Multidisciplinary Approaches and Thoughts on the Care of HER2+ Breast Cancer

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: February 28, 2021
Expires: February 28, 2022
45 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is clinicians/HCPs who treat patients with HER2+ breast cancer inclusive of a multidisciplinary care team (community and academic medical oncologists, surgeons, radiation oncologists, experts in diagnostic imaging, pathologists, oncology nurses, nurse practitioners, genetic counselors, and pharmacists).

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss the role of HER2 in the pathogenesis of breast cancer and the rationale for using HER2-directed therapies in patients with this disease subtype
  • Evaluate clinical trial data of current and emerging therapies for patients with HER2+ breast cancer
  • Develop strategies using a multidisciplinary approach with physicians and nurse/advanced practitioners to address complicated cases of HER2+ breast cancer

Activity Description

Treating patients with cancer is shifting from focusing solely on disease management to more of a patient-centered approach. This includes providing greater attention to psychosocial issues, quality of life, patient empowerment, and survivorship. To address these issues, many institutions are increasingly providing care by multidisciplinary teams. This activity aims to provide community-based clinicians with clinical recommendations to address challenging cases of HER2+ breast cancer via breast cancer experts.

Statement of Educational Need

Because of the volume of research and approvals regarding the use of anti-HER2-based therapies for patients with breast cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with HER2+ breast cancer need expert guidance to evaluate emerging data, use existing anti-HER2-based therapies safely and effectively, and plan strategies to appropriately integrate novel agents into practice when they become available, in consideration of patient needs and preferences.

Agenda

Introduction & The Role of HER2 in Breast Cancer

It Takes a Village: Optimizing the Breast Cancer Care Team

Treating Metastatic HER2+ Breast Cancer

Mitigating and Managing Adverse Events

Key Takeaways

Moderator

Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Cancer Program
Texas Oncology and US Oncology Network
Dallas, Texas

Faculty

Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee


Marissa Marti, APRN, AGNP-C, AOCNP
Nurse Practitioner
Texas Oncology
Baylor Charles A. Sammons Cancer Center
Dallas, Texas

Patient Advocates & Breast Cancer Survivors

Julia Maués


Sheila McGlown

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty

Joyce O'Shaughnessy, MD (Moderator)
Consulting Fees: AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals

Erika Hamilton, MD
Consulting Fees: Pfizer Inc, Genentech/Roche, Lilly, Puma Biotechnology, Daiichi Sankyo, Mersana, Boehringer Ingelheim, AstraZeneca, Novartis, Silverback Therapeutics, Black Diamond, CytomX Therapeutics, Dantari, H3 Biomedicine, Merck, Novartis, Seattle Genetics, Eisai

Grants/Research Support: AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millennium, TapImmune Inc., Lilly, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Takeda, Macrogenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, Inventis Bio, Deciphera, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback, Seattle Genetics, Puma Biotechnology, Compugen, G1 Therapeutics, Karyopharm Therapeutics, Torque, Dana-Farber Cancer Hospital, Infinity Pharmaceuticals, Onconova Therapeutics

Other Financial or Material Support: AstraZeneca, Lilly, Pfizer, Puma Biotechnology, Daiichi Sankyo

Marissa Marti, APRN, AGNP-C, AOCNP
Consulting Fees: Biotheranostics, Inc., Novartis, Puma Biotechnology, Research to Practice, i3 Health

Patient Advocates & Breast Cancer Survivors
Julia Maués
Consultant Fees: AstraZeneca, PUMA, Seattle Genetics, Sanofi

Sheila McGlown
No relevant financial relationships to disclose.

Planning Committee
The following planning committee members have nothing to disclose except for the following:
Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies
Bio Ascend: Chloe Dunnam, Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: February 28, 2021
Expires: February 28, 2022
45 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is clinicians/HCPs who treat patients with HER2+ breast cancer inclusive of a multidisciplinary care team (community and academic medical oncologists, surgeons, radiation oncologists, experts in diagnostic imaging, pathologists, oncology nurses, nurse practitioners, genetic counselors, and pharmacists).

Learning Objectives

After participating in this activity, participants should be better able to:

  • Discuss the role of HER2 in the pathogenesis of breast cancer and the rationale for using HER2-directed therapies in patients with this disease subtype
  • Evaluate clinical trial data of current and emerging therapies for patients with HER2+ breast cancer
  • Develop strategies using a multidisciplinary approach with physicians and nurse/advanced practitioners to address complicated cases of HER2+ breast cancer

Activity Description

Treating patients with cancer is shifting from focusing solely on disease management to more of a patient-centered approach. This includes providing greater attention to psychosocial issues, quality of life, patient empowerment, and survivorship. To address these issues, many institutions are increasingly providing care by multidisciplinary teams. This activity aims to provide community-based clinicians with clinical recommendations to address challenging cases of HER2+ breast cancer via breast cancer experts.

Statement of Educational Need

Because of the volume of research and approvals regarding the use of anti-HER2-based therapies for patients with breast cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with HER2+ breast cancer need expert guidance to evaluate emerging data, use existing anti-HER2-based therapies safely and effectively, and plan strategies to appropriately integrate novel agents into practice when they become available, in consideration of patient needs and preferences.

Agenda

Introduction & The Role of HER2 in Breast Cancer

It Takes a Village: Optimizing the Breast Cancer Care Team

Treating Metastatic HER2+ Breast Cancer

Mitigating and Managing Adverse Events

Key Takeaways

Moderator

Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Cancer Program
Texas Oncology and US Oncology Network
Dallas, Texas

Faculty

Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee


Marissa Marti, APRN, AGNP-C, AOCNP
Nurse Practitioner
Texas Oncology
Baylor Charles A. Sammons Cancer Center
Dallas, Texas

Patient Advocates & Breast Cancer Survivors

Julia Maués


Sheila McGlown

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty

Joyce O'Shaughnessy, MD (Moderator)
Consulting Fees: AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals

Erika Hamilton, MD
Consulting Fees: Pfizer Inc, Genentech/Roche, Lilly, Puma Biotechnology, Daiichi Sankyo, Mersana, Boehringer Ingelheim, AstraZeneca, Novartis, Silverback Therapeutics, Black Diamond, CytomX Therapeutics, Dantari, H3 Biomedicine, Merck, Novartis, Seattle Genetics, Eisai

Grants/Research Support: AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millennium, TapImmune Inc., Lilly, Medivation, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Takeda, Macrogenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, Inventis Bio, Deciphera, Sermonix Pharmaceuticals, Sutro, Aravive, Zenith Epigenetics, Arvinas, Torque, Harpoon, Fochon, Black Diamond, Orinove, Molecular Templates, Silverback, Seattle Genetics, Puma Biotechnology, Compugen, G1 Therapeutics, Karyopharm Therapeutics, Torque, Dana-Farber Cancer Hospital, Infinity Pharmaceuticals, Onconova Therapeutics

Other Financial or Material Support: AstraZeneca, Lilly, Pfizer, Puma Biotechnology, Daiichi Sankyo

Marissa Marti, APRN, AGNP-C, AOCNP
Consulting Fees: Biotheranostics, Inc., Novartis, Puma Biotechnology, Research to Practice, i3 Health

Patient Advocates & Breast Cancer Survivors
Julia Maués
Consultant Fees: AstraZeneca, PUMA, Seattle Genetics, Sanofi

Sheila McGlown
No relevant financial relationships to disclose.

Planning Committee
The following planning committee members have nothing to disclose except for the following:
Sara Fagerlie, PhD, CHCP
Consultant: Adaptive Biotechnologies
Bio Ascend: Chloe Dunnam, Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo.

Contact Information for Questions About the Activity

info@bioascend.com

1.50 CME
Integrity Continuing Education, Inc.
Cracking the Code: Exploring Novel Frontline Treatments and Prospects for Maintenance Therapy in AML

Cracking the Code: Exploring Novel Frontline Treatments and Prospects for Maintenance Therapy in AML

Start

Activity Details

Free CME
1.50 AMA PRA Category 1 Credit(s)
Released: February 25, 2021
Expires: February 25, 2022
90 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for hematologists, oncologists, and hematology/oncology fellows, attendings and trainees.

Learning Objectives

  • Correlate disease pathophysiology, cytogenetic, and molecular characteristics with targeted agents to individualize treatment of patients with acute myeloid leukemia (AML)
  • Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
  • Describe case scenarios in which maintenance therapy may become standard in the near future
  • Evaluate methods for measuring minimal residual disease (MRD) after complete remission to determine risk of relapse

Activity Description

This CME-certified interactive patient simulation on-demand activity will pose a series of questions to participating clinicians and provide immediate, personalized feedback based on individual responses. This activity will be bolstered by the inclusion of multimedia elements, including faculty video, key supporting slides, animations, interactive polling questions, text and graphics, and clinician support tools.

Statement of Educational Need

Once frustratingly slow, treatment advances in acute myeloid leukemia (AML) have been accelerating thanks to improved understanding of disease progression at the molecular level. Several new drug approvals have ended decades of stagnation in a field that had been notorious for lack of progress. Response rates to first and subsequent lines of therapy have been improving, especially among subsets of patients who carry actionable mutations. Nonetheless, relapse remains common. Novel therapies, consolidation chemotherapy, and/or hematopoietic stem cell transplant (HSCT) may prolong remissions, but relapse remains the primary obstacle to long-term survival. For this reason, maintenance therapy has had long-standing appeal and is finally emerging as a viable strategy that can be incorporated into clinical practice.

Faculty

Courtney DiNardo, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas


Eytan M. Stein, MD
Assistant Professor
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Courtney DiNardo, MD
Consulting fees: AbbVie, Agios, BMS/Celgene, Daiichi-Sankyo, ImmuneOnc, Novartis, Takeda
Scientific Advisory Board with Stock Options: Notable Labs

Eytan Stein, MD
Consulting Fees: Agios, Amgen, Astellas, Celgene, Daiichi-Sankyo, Seattle Genetics, Syndax, and Syros
Ownership Interests: Auron Therapeutics

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of February 25, 2021 through February 25, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc.does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Astellas and Bristol Myers Squibb.

Activity Details

Free CME
1.50 AMA PRA Category 1 Credit(s)
Released: February 25, 2021
Expires: February 25, 2022
90 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for hematologists, oncologists, and hematology/oncology fellows, attendings and trainees.

Learning Objectives

  • Correlate disease pathophysiology, cytogenetic, and molecular characteristics with targeted agents to individualize treatment of patients with acute myeloid leukemia (AML)
  • Evaluate recent changes to the standard treatment paradigm for newly diagnosed and relapsed/refractory patients with AML
  • Describe case scenarios in which maintenance therapy may become standard in the near future
  • Evaluate methods for measuring minimal residual disease (MRD) after complete remission to determine risk of relapse

Activity Description

This CME-certified interactive patient simulation on-demand activity will pose a series of questions to participating clinicians and provide immediate, personalized feedback based on individual responses. This activity will be bolstered by the inclusion of multimedia elements, including faculty video, key supporting slides, animations, interactive polling questions, text and graphics, and clinician support tools.

Statement of Educational Need

Once frustratingly slow, treatment advances in acute myeloid leukemia (AML) have been accelerating thanks to improved understanding of disease progression at the molecular level. Several new drug approvals have ended decades of stagnation in a field that had been notorious for lack of progress. Response rates to first and subsequent lines of therapy have been improving, especially among subsets of patients who carry actionable mutations. Nonetheless, relapse remains common. Novel therapies, consolidation chemotherapy, and/or hematopoietic stem cell transplant (HSCT) may prolong remissions, but relapse remains the primary obstacle to long-term survival. For this reason, maintenance therapy has had long-standing appeal and is finally emerging as a viable strategy that can be incorporated into clinical practice.

Faculty

Courtney DiNardo, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
Houston, Texas


Eytan M. Stein, MD
Assistant Professor
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Courtney DiNardo, MD
Consulting fees: AbbVie, Agios, BMS/Celgene, Daiichi-Sankyo, ImmuneOnc, Novartis, Takeda
Scientific Advisory Board with Stock Options: Notable Labs

Eytan Stein, MD
Consulting Fees: Agios, Amgen, Astellas, Celgene, Daiichi-Sankyo, Seattle Genetics, Syndax, and Syros
Ownership Interests: Auron Therapeutics

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of February 25, 2021 through February 25, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc.does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Astellas and Bristol Myers Squibb.

0.50 CME / MOC
The Postgraduate Institute for Medicine
Optimizing Frontline Immunotherapy for High PD-L1 Expressers with NSCLC

Optimizing Frontline Immunotherapy for High PD-L1 Expressers with NSCLC

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)™/
ABIM MOC Points
Released: February 24, 2021
Expires: February 23, 2022
30 minutes to complete

Jointly Provided By

Jointly provided by Postgraduate institute for Medicine and RMEI Medical Education, LLC.

Target Audience

Oncologists and pulmonologists involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Analyze key safety and efficacy data for current and emerging frontline immunotherapy options in advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression levels ≥50%
  • Assess the potential impact of emerging frontline immunotherapeutic approaches on treatment selection in patients with advanced NSCLC and high PD-L1 expression

Activity Description

The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of regimens targeting the PD-1/PD-L1 axis. In this activity, Roy S. Herbst, MD, PhD and Sarah B. Goldberg, MD, MPH, share the latest data for current and emerging checkpoint inhibitor monotherapies in advanced NSCLC with high PD-L1 expression and provide expert guidance on optimizing frontline treatment selection.

Activity Chair

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology
Chief of Medical Oncology

Associate Cancer Center Director, Translational Research
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor of Medicine (Medical Oncology)
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Roy S. Herbst, MD, PhD, has affiliations with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol Myers Squibb, Cybrexa Therapeutics, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Oncternal Therapeutics, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc, Symphogen, Takeda, Tesaro, Tocagen, WindMIL Therapeutics, Xencor, Inc. (Consulting); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company (Contracted Research); Junshi Pharmaceuticals (Board Member).

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Regeneron, Sanofi Genzyme (Consulting); AstraZeneca, Boehringer Ingelheim (ContractedResearch).

Planners and Managers
The PIM planners and managers have nothing to disclose. The RMEI Medical Education, LLC, planners and managers have nothing to disclose.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)™/
ABIM MOC Points
Released: February 24, 2021
Expires: February 23, 2022
30 minutes to complete

Jointly Provided By

Jointly provided by Postgraduate institute for Medicine and RMEI Medical Education, LLC.

Target Audience

Oncologists and pulmonologists involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Analyze key safety and efficacy data for current and emerging frontline immunotherapy options in advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression levels ≥50%
  • Assess the potential impact of emerging frontline immunotherapeutic approaches on treatment selection in patients with advanced NSCLC and high PD-L1 expression

Activity Description

The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of regimens targeting the PD-1/PD-L1 axis. In this activity, Roy S. Herbst, MD, PhD and Sarah B. Goldberg, MD, MPH, share the latest data for current and emerging checkpoint inhibitor monotherapies in advanced NSCLC with high PD-L1 expression and provide expert guidance on optimizing frontline treatment selection.

Activity Chair

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology
Chief of Medical Oncology

Associate Cancer Center Director, Translational Research
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT

Faculty

Sarah B. Goldberg, MD, MPH
Associate Professor of Medicine (Medical Oncology)
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Roy S. Herbst, MD, PhD, has affiliations with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol Myers Squibb, Cybrexa Therapeutics, eFFECTOR Therapeutics, Inc., Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Oncternal Therapeutics, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc, Symphogen, Takeda, Tesaro, Tocagen, WindMIL Therapeutics, Xencor, Inc. (Consulting); AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company (Contracted Research); Junshi Pharmaceuticals (Board Member).

Sarah B. Goldberg, MD, MPH, has affiliations with AstraZeneca, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Regeneron, Sanofi Genzyme (Consulting); AstraZeneca, Boehringer Ingelheim (ContractedResearch).

Planners and Managers
The PIM planners and managers have nothing to disclose. The RMEI Medical Education, LLC, planners and managers have nothing to disclose.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact PIM at inquiries@pimed.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation form and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

0.25 CME
University of Nebraska Medical Center
Experts Debate Optimal Approaches to the Treatment of Multiple Myeloma CME

Experts Debate Optimal Approaches to the Treatment of Multiple Myeloma CME

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 1, 2021
Expires: February 1, 2022
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate clinical trial results of frontline treatment options that are available for the treatment of patients with newly diagnosed MM
  • Review maintenance therapy strategies for patients with MM that are eligible to receive this type of therapy
  • Assess treatment approaches and sequencing of therapy for patients with relapsed and/or refractory MM
  • Optimize approaches to manage treatment-related adverse events that may occur during the treatment of patients with MM
  • Discuss clinical trials results that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will provide the most up-to-date information to clinicians treating patients with MM, strategies to evaluate best practices and emerging clinical data, and expert insights on how to apply them safely and effectively to your patients.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia

Pieter Sonneveld, MD, PhD
Professor of Hematology
Erasmus MC Cancer Institute/University Medical Center
Rotterdam, The Netherlands

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Pieter Sonneveld, MD, PhD
Employment: Hematology, Erasmus MC Cancer Institute, Rotterdam
Discussion of off-label drug use: Not Applicable
Research support: Amgen Inc., Celgene Corporation, Janssen, Karyopharm Therapeutics, SkylineDx
Advisory Boards: Amgen Inc., BMS/Celgene, Janssen, Karyopharm Therapeutics, Oncopeptides, SkylineDx, Seattle Genetics

Chair European Myeloma Network
Chair Hovon Myeloma Working Group

Planning Committee
The following planning committee members have nothing to disclose:
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Oncopeptides.

Contact Information for Questions About the Activity

info@bioascend.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: February 1, 2021
Expires: February 1, 2022
15 minutes to complete

Accredited By

The University of Nebraska Medical Center

Target Audience

The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Evaluate clinical trial results of frontline treatment options that are available for the treatment of patients with newly diagnosed MM
  • Review maintenance therapy strategies for patients with MM that are eligible to receive this type of therapy
  • Assess treatment approaches and sequencing of therapy for patients with relapsed and/or refractory MM
  • Optimize approaches to manage treatment-related adverse events that may occur during the treatment of patients with MM
  • Discuss clinical trials results that are investigating emerging novel agents in patients with MM

Activity Description

Major advances in the diagnosis and treatment of multiple myeloma (MM) have occurred in the past decade. In the future, studies will continue to address issues such as optimal sequencing of therapies, the incorporation of novel agents as they are approved into existing regimens, the role of MRD, optimal treatment of high-risk disease, and early interventions as a potential cure. This educational activity will provide the most up-to-date information to clinicians treating patients with MM, strategies to evaluate best practices and emerging clinical data, and expert insights on how to apply them safely and effectively to your patients.

Statement of Educational Need

Given the recent approval of various therapies for the treatment of patients with multiple myeloma (MM), as well as the associated volume of emerging data of investigational agents, it is critical that oncologists and hematologists be able to evaluate the benefits of these agents, select appropriate patients for therapy or clinical trials, and prevent and manage AEs. Thus, we propose to facilitate evaluation of emerging scientific and clinical data, and appropriate use of current and emerging therapies, by clinicians who treat patients with MM.

Faculty

Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Atlanta, Georgia

Pieter Sonneveld, MD, PhD
Professor of Hematology
Erasmus MC Cancer Institute/University Medical Center
Rotterdam, The Netherlands

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Conflict of Interest Policy/Disclosure Statement

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

Faculty
Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis

Pieter Sonneveld, MD, PhD
Employment: Hematology, Erasmus MC Cancer Institute, Rotterdam
Discussion of off-label drug use: Not Applicable
Research support: Amgen Inc., Celgene Corporation, Janssen, Karyopharm Therapeutics, SkylineDx
Advisory Boards: Amgen Inc., BMS/Celgene, Janssen, Karyopharm Therapeutics, Oncopeptides, SkylineDx, Seattle Genetics

Chair European Myeloma Network
Chair Hovon Myeloma Working Group

Planning Committee
The following planning committee members have nothing to disclose:
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC and Bio Ascend.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the University of Nebraska Medical Center and Bio Ascend. The University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by independent educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Oncopeptides.

Contact Information for Questions About the Activity

info@bioascend.com

Pages